VivoSeq
Musculoskeletal

Anterior Cruciate Ligament Reconstruction

0

Pipeline Programs

8

Active Trials

0

Companies Involved

Anterior Cruciate Ligament Reconstruction is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

6/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

36

clinical trials

Completed21 · 58%
Unknown status5 · 14%
Recruiting4 · 11%
Not yet recruiting3 · 8%
Withdrawn1 · 3%
Active, not recruiting1 · 3%
Other1 · 3%

Trial Activity

36 trials

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)